News
Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...
Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade ...
Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.
The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve ...
What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback